Component

Platelet thromboxane A2 production in vitro

Platelet thromboxane A2 production in vitro. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Curcumin inhibited platelet thromboxane A2 formation.

    Curcumin → Platelet thromboxane A2 production in vitro source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/curcumin-research/10484074.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a7f693540f3a0c4db6b93f1ce8c2adaadd1647a6234091da685497bdf66c2b1a", "start_char": 0, "end_char": 1375, "text_sha256": "a7f693540f3a0c4db6b93f1ce8c2adaadd1647a6234091da685497bdf66c2b1a"}
    experimental_model
    Isolated platelet aggregation and signaling assays
    exposure
    Curcumin: PAF/arachidonic-acid aggregation IC50 about 20-25 micromolar, thromboxane IC50 about 70 micromolar
    limitations
    In-vitro concentrations are not proof of clinical bleeding risk or an anticoagulant treatment effect; fluorescence-based calcium readout is assay-specific.
    nutrient_topic
    Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
    organism
    Platelets; donor species not resolved in indexed abstract
    plain_language
    One platelet-activating signal was reduced.
    primary_references
    [curcumin-p10484074] Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. (1999). https://pubmed.ncbi.nlm.nih.gov/10484074/ DOI: 10.1016/s0006-2952(99)00206-3
    tissue_or_cell_type
    Platelet activation and calcium signaling

    Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 996–1007

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Isolated platelet aggregation and signaling assays · source_derived_draft · unverified_draft

    ### curcumin-platelet-thromboxane Curcumin inhibited platelet thromboxane A2 formation. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: One platelet-activating signal was reduced. organism: Platelets; donor species not resolved in indexed abstract tissue_or_cell_type: Platelet activation and calcium signaling experimental_model: Isolated platelet aggregation and signaling assays limitations: In-vitro concentrations are not proof of clinical bleeding risk or an anticoagulant treatment effect; fluorescence-based calcium readout is assay-specific. exposure: Curcumin: PAF/arachidonic-acid aggregation IC50 about 20-25 micromolar, thromboxane IC50 about 70 micromolar evidence_span: {"source_cache": "artifacts/curcumin-research/10484074.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a7f693540f3a0c4db6b93f1ce8c2adaadd1647a6234091da685497bdf66c2b1a", "start_char": 0, "end_char": 1375, "text_sha256": "a7f693540f3a0c4db6b93f1ce8c2adaadd1647a6234091da685497bdf66c2b1a"} [curcumin-p10484074] Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. (1999). https://pubmed.ncbi.nlm.nih.gov/10484074/ DOI: 10.1016/s0006-2952(99)00206-3
    Complete structured claim and evidence

  2. Acetaminophen has potent antipyretic and analgesic actions but very weak anti-inflammatory activity, and when administered to humans it reduces levels of prostaglandin metabolites in urine but does not reduce synthesis of prostaglandins by blood platelets or by the stomach mucosa; because it is a weak inhibitor in vitro of both cyclooxygenase-1 and -2 the possibility exists that it inhibits a so far unidentified form, and in animal studies cyclooxygenase in homogenates of different tissues varies in sensitivity to its inhibitory action, which may be evidence that there are more than two isoforms.

    Paracetamol → Platelet thromboxane A2 production in vitro source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/paracetamol-research/11113024.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f3d9785240d2bc30e79775035576d3b017471500c110d627653e6fd80e820eee", "start_char": 0, "end_char": 1012, "text_sha256": "f3d9785240d2bc30e79775035576d3b017471500c110d627653e6fd80e820eee"}
    experimental_model
    Review of the evidence for an unidentified cyclooxygenase form, written before COX-3 was cloned
    exposure
    Acetaminophen compared against its effects on urinary prostaglandin metabolites and on platelet and gastric prostaglandin synthesis
    limitations
    A review that states the puzzle precisely before an answer existed. The human observations it collects are the clinical signature any mechanism has to explain.
    nutrient_topic
    Paracetamol research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from the metabolites NAPQI and AM404. · Paracetamol
    organism
    Human and animal
    plain_language
    It lowers prostaglandins measured in urine while leaving the platelet and the stomach alone, and that is the puzzle every account has to solve.
    primary_references
    [apap-p11113024] Mechanism of action of acetaminophen: is there a cyclooxygenase 3? (2000). https://pubmed.ncbi.nlm.nih.gov/11113024/ DOI: 10.1086/317520
    tissue_or_cell_type
    Platelets, gastric mucosa and tissue homogenates

    Paracetamol: the enzyme it reduces rather than blocks, the isoform that turned out not to exist, the metabolite that carries the analgesia, and the metabolite that destroys the liver (2026-09-22) · lines 207–218

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Review of the evidence for an unidentified cyclooxygenase form, written before COX-3 was cloned · source_derived_draft · unverified_draft

    ### apap-the-puzzle-stated Acetaminophen has potent antipyretic and analgesic actions but very weak anti-inflammatory activity, and when administered to humans it reduces levels of prostaglandin metabolites in urine but does not reduce synthesis of prostaglandins by blood platelets or by the stomach mucosa; because it is a weak inhibitor in vitro of both cyclooxygenase-1 and -2 the possibility exists that it inhibits a so far unidentified form, and in animal studies cyclooxygenase in homogenates of different tissues varies in sensitivity to its inhibitory action, which may be evidence that there are more than two isoforms. Condition category: normal nutrient_topic: Paracetamol research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from the metabolites NAPQI and AM404. plain_language: It lowers prostaglandins measured in urine while leaving the platelet and the stomach alone, and that is the puzzle every account has to solve. organism: Human and animal tissue_or_cell_type: Platelets, gastric mucosa and tissue homogenates experimental_model: Review of the evidence for an unidentified cyclooxygenase form, written before COX-3 was cloned limitations: A review that states the puzzle precisely before an answer existed. The human observations it collects are the clinical signature any mechanism has to explain. exposure: Acetaminophen compared against its effects on urinary prostaglandin metabolites and on platelet and gastric prostaglandin synthesis evidence_span: {"source_cache": "artifacts/paracetamol-research/11113024.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f3d9785240d2bc30e79775035576d3b017471500c110d627653e6fd80e820eee", "start_char": 0, "end_char": 1012, "text_sha256": "f3d9785240d2bc30e79775035576d3b017471500c110d627653e6fd80e820eee"} [apap-p11113024] Mechanism of action of acetaminophen: is there a cyclooxygenase 3? (2000). https://pubmed.ncbi.nlm.nih.gov/11113024/ DOI: 10.1086/317520
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. In vitro acetaminophen elicited a 4.4-fold selectivity toward cyclooxygenase-2 inhibition with half-maximal inhibitory concentrations of 113.7 micromolar for cyclooxygenase-1 and 25.8 micromolar for cyclooxygenase-2, following a single oral 1000 milligram dose maximal ex vivo inhibitions were 56% for cyclooxygenase-1 and 83% for cyclooxygenase-2, plasma concentrations remained above the in vitro cyclooxygenase-2 value for at least 5 hours, and ex vivo values compared favourably with in vitro ones; acetaminophen inhibited cyclooxygenase-2 by more than 80%, comparable to non-steroidal anti-inflammatory drugs and selective inhibitors, but the greater than 95% cyclooxygenase-1 blockade relevant for suppression of platelet function was not achieved, and in view of its substantial cyclooxygenase-2 inhibition the cardiovascular warnings defined for selective inhibitors should also be considered.

    Paracetamol → Cyclooxygenase-2 (PTGS2) source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/paracetamol-research/17884974.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e2856e9fc1c319219fd3d3cb145f70bb1157f7ca0baa0221594c9583cf7ddc23", "start_char": 0, "end_char": 1857, "text_sha256": "e2856e9fc1c319219fd3d3cb145f70bb1157f7ca0baa0221594c9583cf7ddc23"}
    experimental_model
    Ex vivo and in vitro human whole blood cyclooxygenase assays in five volunteers given a single oral dose
    exposure
    1000 milligrams oral acetaminophen, with coagulation-induced thromboxane B2 and lipopolysaccharide-induced prostaglandin E2 as isoform indices
    limitations
    Measures both isoform indices in dosed people and relates them to plasma concentration. Five volunteers and a single dose.
    nutrient_topic
    Paracetamol research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from the metabolites NAPQI and AM404. · Paracetamol
    organism
    Human
    plain_language
    In people it blocks the second enzyme as hard as a proper anti-inflammatory does, and never blocks the first enough to touch platelets.
    primary_references
    [apap-p17884974] Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. (2008). https://pubmed.ncbi.nlm.nih.gov/17884974/ DOI: 10.1096/fj.07-8506com
    tissue_or_cell_type
    Whole blood

    Paracetamol: the enzyme it reduces rather than blocks, the isoform that turned out not to exist, the metabolite that carries the analgesia, and the metabolite that destroys the liver (2026-09-22) · lines 259–270

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Ex vivo and in vitro human whole blood cyclooxygenase assays in five volunteers given a single oral dose · source_derived_draft · unverified_draft

    ### apap-four-fold-cox2-selective-in-man In vitro acetaminophen elicited a 4.4-fold selectivity toward cyclooxygenase-2 inhibition with half-maximal inhibitory concentrations of 113.7 micromolar for cyclooxygenase-1 and 25.8 micromolar for cyclooxygenase-2, following a single oral 1000 milligram dose maximal ex vivo inhibitions were 56% for cyclooxygenase-1 and 83% for cyclooxygenase-2, plasma concentrations remained above the in vitro cyclooxygenase-2 value for at least 5 hours, and ex vivo values compared favourably with in vitro ones; acetaminophen inhibited cyclooxygenase-2 by more than 80%, comparable to non-steroidal anti-inflammatory drugs and selective inhibitors, but the greater than 95% cyclooxygenase-1 blockade relevant for suppression of platelet function was not achieved, and in view of its substantial cyclooxygenase-2 inhibition the cardiovascular warnings defined for selective inhibitors should also be considered. Condition category: normal nutrient_topic: Paracetamol research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from the metabolites NAPQI and AM404. plain_language: In people it blocks the second enzyme as hard as a proper anti-inflammatory does, and never blocks the first enough to touch platelets. organism: Human tissue_or_cell_type: Whole blood experimental_model: Ex vivo and in vitro human whole blood cyclooxygenase assays in five volunteers given a single oral dose limitations: Measures both isoform indices in dosed people and relates them to plasma concentration. Five volunteers and a single dose. exposure: 1000 milligrams oral acetaminophen, with coagulation-induced thromboxane B2 and lipopolysaccharide-induced prostaglandin E2 as isoform indices evidence_span: {"source_cache": "artifacts/paracetamol-research/17884974.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e2856e9fc1c319219fd3d3cb145f70bb1157f7ca0baa0221594c9583cf7ddc23", "start_char": 0, "end_char": 1857, "text_sha256": "e2856e9fc1c319219fd3d3cb145f70bb1157f7ca0baa0221594c9583cf7ddc23"} [apap-p17884974] Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. (2008). https://pubmed.ncbi.nlm.nih.gov/17884974/ DOI: 10.1096/fj.07-8506com
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards